Faithward Advisors LLC Buys 9,065 Shares of Jazz Pharmaceuticals PLC $JAZZ

Faithward Advisors LLC increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 31.0% during the 1st quarter, HoldingsChannel reports. The firm owned 38,339 shares of the specialty pharmaceutical company’s stock after buying an additional 9,065 shares during the period. Jazz Pharmaceuticals comprises 1.0% of Faithward Advisors LLC’s holdings, making the stock its 25th largest position. Faithward Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $7,717,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cardinal Capital Management raised its stake in Jazz Pharmaceuticals by 0.5% during the 4th quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company’s stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Jazz Pharmaceuticals by 9.0% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 983 shares of the specialty pharmaceutical company’s stock worth $130,000 after buying an additional 81 shares during the last quarter. UMB Bank n.a. grew its holdings in shares of Jazz Pharmaceuticals by 12.6% in the fourth quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 81 shares during the period. Pinnacle Associates Ltd. increased its position in Jazz Pharmaceuticals by 0.7% during the fourth quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company’s stock valued at $1,905,000 after acquiring an additional 83 shares during the last quarter. Finally, Fairbanks Capital Management Inc. increased its position in Jazz Pharmaceuticals by 0.4% during the third quarter. Fairbanks Capital Management Inc. now owns 25,023 shares of the specialty pharmaceutical company’s stock valued at $3,298,000 after acquiring an additional 94 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Price Performance

NASDAQ JAZZ opened at $230.25 on Wednesday. The business’s fifty day moving average is $222.61 and its 200 day moving average is $191.53. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a market capitalization of $14.46 billion, a PE ratio of -11,506.75, a price-to-earnings-growth ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a return on equity of 14.56% and a net margin of 0.66%.The business had revenue of $1.07 billion during the quarter. Sell-side analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current year.

Insider Activity at Jazz Pharmaceuticals

In related news, Director Heather Ann Mcsharry sold 2,000 shares of the stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $241.00, for a total value of $482,000.00. Following the completion of the sale, the director directly owned 18,449 shares of the company’s stock, valued at approximately $4,446,209. This represents a 9.78% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mark Douglas Smith sold 1,157 shares of the firm’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $230.55, for a total transaction of $266,746.35. Following the sale, the director owned 9,680 shares in the company, valued at approximately $2,231,724. The trade was a 10.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 13,098 shares of company stock worth $2,832,086 in the last quarter. 4.10% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

JAZZ has been the topic of several research reports. Truist Financial set a $256.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, June 9th. TD Cowen upped their price target on shares of Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, May 6th. Morgan Stanley reiterated an “overweight” rating and issued a $245.00 price objective on shares of Jazz Pharmaceuticals in a research note on Thursday, May 7th. Wells Fargo & Company raised their price objective on shares of Jazz Pharmaceuticals from $250.00 to $265.00 and gave the stock an “overweight” rating in a report on Wednesday, May 6th. Finally, UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their target price for the company from $188.00 to $307.00 in a research report on Tuesday, May 19th. Sixteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $246.06.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.